Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Inclusion Criteria:

• Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens ofsystem therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD),and anti-CD38 antibody (CD38mab); or has "triple-refractory" disease

• Documented measurable disease

• Adequate organ function

• Life expectancy > 12 weeks, Eastern Cooperative Group Performance Status 0-1

Exclusion Criteria:

• Plasma Cell Leukemia or History of Plasma Cell Leukemia

• Patients with a history of severe hypersensitivity to DMSO should be excluded

• Contraindication to fludarabine or cyclophosphamide

• Severe uncontrolled intercurrent illness (e.g., infection) or laboratoryabnormalities

• Active central nervous system disease involvement by malignancy or active CNSpathology